



## Company Announcement

### Nykode Therapeutics to Regain Control of VB10.NEO Program

Oslo, Norway, November 7, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has received notification from Genentech, a member of the Roche group, of its decision to terminate the collaboration and licensing agreement for Nykode’s VB10.NEO cancer vaccine program.

With this notice, the existing collaboration and licensing agreement signed September 2020 will terminate effective January 6, 2025 and Nykode will regain control of VB10.NEO and its intellectual property portfolio along with rights to license the program. Nykode is not required to refund any upfront payments or make any future payments to Genentech on the termination.

“We remain confident in the clinical data generated so far and the continued potential of our personalized cancer vaccine VB10.NEO, and will determine the optimal path forward for the program, including potential new partnerships”, said Michael Engsig, Chief Executive Officer of Nykode Therapeutics.

Nykode plans to host a webcast tomorrow morning CET to provide further details and answer questions about this development. Information regarding the time, and access details for the webcast will be shared in a subsequent announcement.

#### **About VB10.NEO**

VB10.NEO is a proprietary individualized neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors. The vaccine is designed to be produced on-demand according to the neoantigen profile of an individual patient. Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues and are thus an attractive target for cancer immunotherapy as they may be recognized as foreign by the immune system. VB10.NEO has been evaluated in multiple indications in two clinical trials. It has been shown to be generally well tolerated and with an ability to generate uniquely broad patient- and tumor-specific long-lasting immune responses.

#### **About Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), employed with their cancer vaccines to induce a broad, strong and long-lasting antigen specific immune response, which correlates with clinical responses in cancer patients.



Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies, which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is being investigated in a trial with more than 10 different indications.

The Company's partnerships include a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

#### **Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

#### **Contact for Nykode Therapeutics ASA:**

Alexandra Deschner, Head of IR  
Nykode Therapeutics ASA  
[IR@nykode.com](mailto:IR@nykode.com)

#### **Nykode Therapeutics ASA**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway